Small Pharma’s Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Innovator Embraces Psychedelic Horizons With New Schedule 1 Manufacturing License
A new player is entering the psychedelics production space.
Compass’ Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows
UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa.
They recently shared what are believed to be the first results from such a research study, and the findings look promising.
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
Cybin One Steps Away From Complete Dosing
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa’s Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People'
Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal prosecution for possession, use, purchase, cultivation and engaging in practices with “entheogenic plants or plant compounds."
A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use
A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance.
Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy’s Garden And More
GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote
Filament Health Uplisting To NASDAQ In A $210M SPAC Deal
Canadian clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF) has entered into a definitive agreement with Jupiter Acquisition Corp. (NASDAQ: JAQC), a Special Purpose Acquisition Company (SPAC) for the creation of a
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph,
PharmaTher’s DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.